Failure of PDE5 inhibitor use: a case of nonresponder? (CME).
Chung
Eric
E
Department of Urology, St Joseph Health Care Hospital, London, ON, Canada.
D002243:Carbolines / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D018783:Impotence, Vasculogenic / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D010348:Patient Care Team; D010410:Penile Erection / Q000187:drug effects; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D012017:Referral and Consultation; D012307:Risk Factors; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use; D000068581:Tadalafil; D017211:Treatment Failure; D014227:Triazines / Q000627:therapeutic use; D000069058:Vardenafil Dihydrochloride; D014665:Vasodilator Agents / Q000627:therapeutic use*
D002243:Carbolines; D007093:Imidazoles; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D014665:Vasodilator Agents; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate